Radiation beads before liver transplant or surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment that delivers tiny radioactive beads directly to liver tumors to shrink them, which may help patients become eligible for a liver transplant or surgery. It is for people with liver cancer that has not spread outside the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have liver cancer that can be seen on a CT or MRI scan.
- You have not had prior cancer treatment for your liver, or you have had a new tumor after certain local treatments like TACE, ablation, or surgery.
- Your cancer is within specific size and number limits (for bridging or downstaging to transplant).
- Your liver function is good (Child-Pugh score A or B7) and you are otherwise healthy enough for the procedure (ECOG 0 or 1).
- You are not pregnant or breastfeeding, and you agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using tiny radioactive beads (TheraSphere) to target and destroy liver tumors in people with early-stage liver cancer. It aims to confirm the safety and effectiveness of a new way to plan the treatment.
This trial tests a treatment called radioembolization for small liver cancers. Radioembolization delivers tiny radioactive beads to the tumor, and the goal is to see if it helps shrink or control the cancer.
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.
This trial tests a targeted internal radiation treatment for people with liver cancer (HCC) that is too widespread for surgery and goes beyond the up-to-7 criteria. It aims to see if this therapy can safely and effectively treat tumors that are all located in a specific area of the liver.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.